Navigation Links
Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function

TORONTO, June 1 /PRNewswire/ -- The final results of the Spare the Nephron (STN) study, a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil), showed the CellCept-based regimen in combination with sirolimus (SRL) is associated with improved renal function when compared with the CellCept-based regimen in combination with calcineurin inhibitors (CNI).

Furthermore, the study showed this improvement without increasing the risk of acute rejection, and was tolerated in almost 80 percent of patients. The results were presented today at the American Transplant Congress (ATC) in Toronto.

The STN Trial in kidney transplant recipients examines ways to prevent rejection without damaging kidneys. As transplant patients are living longer, studies suggest that therapies such as CNIs can cause impairment of kidney function, damage to the blood vessels, and filtering capacity of the kidneys. "This study provides strong evidence for the benefits of a CNI-free, CellCept-based regimen," said Thomas Pearson, M.D., lead investigator, Livingston Professor of Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, GA.

The STN trials were conducted at more than 35 transplant centers in the United States and Canada.

"The goal of this study was to optimize the use of immunosuppressants for achieving long-term success," added Dr. Pearson. "The STN Kidney studied the combination of CellCept and SRL with the goal of reducing CNI associated nephrotoxicity therapy to prolong graft and patient survival."

About the Study

This open-label, prospective, multicenter study, randomized 305 patients (maintained on MMF and a CNI) for 30-180 days post-transplant to receive either MMF (1-1.5 g BID) plus SRL (2-10 mg followed by at least 2 mg/day; trough 5-10 ng/mL) and discontinue the CNI (MMF/SRL) or to continue their current regimen (MMF/CNI). Antibody induction and/or corticosteroids were administered according to individual center practices.

Study Results

The 12-month results are from the first 249 patients receiving either the CellCept-based regimen in combination with SRL (n=123) or the CellCept-based regimen in combination with CNI (n=126).

Investigators found acute rejection in 6.5 percent of the patients (8/123) in the CellCept-based regimen in combination with SRL, compared to 7.1 percent of the patients (9/126) in the CellCept-based regimen in combination with CNI.

Mean time from transplant to randomization in both groups was 117 days. Baseline characteristics and measured GFR values were similar in the treatment groups and 98 patients in the CellCept-based regimen in combination with SRL were receiving tacrolimus. Graft loss was experienced in 1.6 percent of patients (2/123) in the CellCept-based regimen in combination with SRL, compared to 2.4 percent of patients (3/126) in the CellCept-based regimen in combination with CNI.

There were no deaths in the CellCept-based regimen in combination with SRL. Three (3/126) patient deaths were remotely related to the CellCept-based regimen in combination with CNI. The number and proportion of patients withdrawn for adverse events at 12 months was 18.7 percent (23/123) in the CellCept-based regimen in combination with SRL, and 7.1 percent (9/126) in the CellCept-based regimen in combination with CNI.

The percent change from baseline in GFR at 12 months was 25.8 percent for patients in the CellCept-based regimen in combination with SRL, compared to 11.3 percent in the CellCept-based regimen in combination with CNI group. Safety outcomes were similar in both groups.

CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.

Important Safety Information:


Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

Female users of childbearing potential must use contraception. Physicians should inform female patients that CellCept use during pregnancy is associated with increased rates of pregnancy loss and congenital malformations.

-- Patients receiving immunosuppressive regimens involving combinations of

drugs, including CellCept, as part of an immunosuppressive regimen are

at increased risk of developing lymphomas and other malignancies,

particularly of the skin.

-- Oversuppression of the immune system can also increase susceptibility

to infection, including opportunistic infections, and sepsis.

-- Cases of progressive multifocal leukoencephalopathy (PML), sometimes

fatal, have been reported in patients treated with CellCept.

Hemiparesis, apathy, confusion, cognitive deficiencies and ataxia were

the most frequent clinical features observed. The reported cases

generally had risk factors for PML, including treatment with

immunosuppressant therapies and impairment of immune function. In

immunosuppressed patients, physicians should consider PML in the

differential diagnosis in patients reporting neurological symptoms and

consultation with a neurologist should be considered as clinically

indicated. Consideration should be given to reducing the amount of

immunosuppression in patients who develop PML. In transplant patients,

physicians should also consider the risk that reduced immunosuppression

represents to the graft.

-- CellCept can cause fetal harm when administered to a pregnant woman. A

patient who is planning a pregnancy should not use CellCept unless she

cannot be successfully treated with other immunosuppressant drugs. If

this drug is used during pregnancy, or if the patient becomes pregnant

while taking this drug, the patient should be apprised of the potential

hazard to the fetus.

-- Women of childbearing potential (including pubertal girls and

peri-menopausal women) taking CellCept must receive contraceptive

counseling and use effective contraception. The patient should begin

using her chosen contraceptive method 4 weeks prior to starting

CellCept therapy. She should continue contraceptive use during therapy

and for 6 weeks after stopping CellCept. Two reliable forms of

contraception must be used simultaneously unless abstinence is the

chosen method. Patients should be aware that CellCept reduces blood

levels of the hormones in the oral contraceptive pill and could

theoretically reduce its effectiveness.

-- Severe neutropenia [absolute neutrophil count (ANC) <0.5 x

10cubed/microL] developed in up to 2.0% of renal, up to 2.8% of cardiac,

and up to 3.6% of hepatic transplant patients receiving CellCept 3 g

daily. Patients receiving CellCept should be monitored for neutropenia.

If neutropenia develops (ANC < 1.3 x 10cubed/microL), dosing with

CellCept should be interrupted or the dose reduced, appropriate

diagnostic tests performed, and the patient managed appropriately (see


-- Gastrointestinal bleeding (requiring hospitalization) has been observed

in approximately 3% of renal, in 1.7% of cardiac, and in 5.4% of

hepatic transplant patients treated with CellCept 3 g daily.

-- Common adverse 20% of patients in CellCept group in controlled events

that were reported in greater than or equal to studies in prevention of

renal, cardiac or hepatic allograft rejection are listed in Table 8 of

the ADVERSE REACTIONS section of the complete Prescribing Information.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News, one of the Top 20 Employers (Science) and ranked the No. 1 Company to Sell For (Selling Power). In previous years, Roche has been named as a Top Company for Older Workers (AARP) and one of the Best Companies to Work For in America (Fortune). For additional information about the U.S. pharmaceuticals business, visit our website Product and treatment information for U.S. healthcare professionals is available at

All trademarks used or mentioned in this release are protected by law.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
2. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
3. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
9. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Clariant, a world leader in specialty ... facility in Belen, New Mexico , has ... including desiccant canisters and packets and other ... plant is the second Clariant site – the first in ... the ISO 15378:2011 standards, following only the Clariant manufacturing facility ...
(Date:10/8/2015)... , Oct. 8, 2015  Nektar Therapeutics (Nasdaq: ... pain and oncology portfolio during an Investor and Analyst ... p.m. Eastern Time in New York City ... of the NKTR-214 Phase 1/2 clinical program and biomarker ... cytokine designed to preferentially stimulate the production of CD8-positive ...
(Date:10/8/2015)... a clinical stage drug development company focused on advancing ... today the commencement of the US arm of an ... acebilustat, in patients with cystic fibrosis (CF). The study ... the United States and European Union, ... 2016. This landmark clinical trial testing once-daily oral acebilustat ...
Breaking Medicine Technology:
... Texas, Dec. 2, 2010 Ascension Orthopedics, Inc., ... another implantation of the TITAN™ Modular Total Shoulder. ... at Bucks County Specialty Hospital in Bensalem, Pennsylvania. ... postoperative x-rays showed a very anatomic replacement.  The ...
... 2, 2010 Medical devices, biotechnology and IT products ... will present to United States investors and the business ... business and investment opportunities. (Logo: ... successful Chilean Small and Medium Enterprises (SMEs) was selected ...
Cached Medicine Technology:
(Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
(Date:10/10/2015)... , ... October 10, 2015 , ... Isabel Healthcare will ... , On the heels of the release of the Institute of Medicine’s latest report ... their integration with Cerner solutions that assist healthcare providers and consumers to potentially reduce ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic ... for Graduate Medical Education J. Michael Finley, DO, as the recipient of the ... for his impact on graduate medical education opportunities for osteopathic residents, and his ...
(Date:10/9/2015)... ... 2015 , ... A new health tool that helps identify if a sore ... ) – just in time for the cold and flu season, which the ... many in the U.S., the real start of cold/flu season is the start of ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington ... orthodontic system that uses clear, plastic aligners. This alternative to braces has become ... which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, ...
Breaking Medicine News(10 mins):
... serious problem that can often be fatal. Methadone has ... addicts. However, the major concern in treating heroin addicts ... is one reason methadone therapy is usually only given ... that an alternative drug therapy combined with psychosocial treatment ...
... researchers are currently testing the safety of hypothermia ... injury. Hypothermia treatment has been shown to be ... but its effectiveness in treating children with traumatic ... decreases inflammation, excitotoxicity (excessive neurotransmitters released with injury ...
... of skin cancer and it has been shown through previous ... sunlight, whose UV rays cause damage to DNA that triggers ... are more prone than others to melanoma. Researchers have now ... people with melanoma that those with fair skin// have lowered ...
... Affective Disorder(SAD) is not all that well understood, but ... sunlight in the winter months. Winter depression involves suffering ... days get longer and nights get shorter. Other SAD ... sleeping for longer than usual. Researchers have now found ...
... hospital in Kolkatta, India recently received a patient, a two-month-old ... suffering from a rare disease caused due to a deficiency ... of 10 million children. Doctors said that the baby was ... On detection the baby, a boy child, was found to ...
... time to its ultraviolet rays, has always been said to be ... shown that even moderate sun exposure can result in moles that ... to sun has been shown as the main risk factor for ... rarest type of skin cancer, is much weaker. It has however, ...
Cached Medicine News:
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: